Hypertrophic cardiomyopathy surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 14: | Line 14: | ||
|- | |- | ||
| bgcolor="LightGreen"|'''1.''' Patients with advanced [[heart failure]] (end stage) and nonobstructive HCM not otherwise amenable to other treatment interventions, with EF less than or equal to 50% (or occasionally with preserved EF), should be considered for heart transplantation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Patients with advanced [[heart failure]] (end stage) and nonobstructive HCM not otherwise amenable to other treatment interventions, with EF less than or equal to 50% (or occasionally with preserved EF), should be considered for heart transplantation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|'''2.''' Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])<nowiki>"</nowiki> | ||
|} | |} | ||
| Line 24: | Line 24: | ||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | ||
|- | |- | ||
|bgcolor="LightCoral"| | |bgcolor="LightCoral"| <nowiki>"</nowiki>'''1.''' Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki> | ||
'''1.''' Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) | |||
|} | |} | ||
Revision as of 04:51, 3 October 2012
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy surgery On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy surgery |
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1], Cafer Zorkun, M.D. [2], Caitlin J. Harrigan [3], Martin S. Maron, M.D., and Barry J. Maron, M.D.
Cardiac transplantation
Cardiac transplantation can be performed in patients with HOCM and has been associated with better post-operative survival than those patients transplanted for ischemic cardiomyopathy [1].
In cases that are refractory to all other forms of treatment, cardiac transplantation is an option.
2011 ACCF/AHA Guideline Recommendations for Selection of Patients for Heart Transplantation (DO NOT EDIT)
| Class I |
| "1. Patients with advanced heart failure (end stage) and nonobstructive HCM not otherwise amenable to other treatment interventions, with EF less than or equal to 50% (or occasionally with preserved EF), should be considered for heart transplantation. (Level of Evidence: B) " |
| "2. Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation. (Level of Evidence: C)" |
| Class III (Harm) |
| "1. Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. (Level of Evidence: C) " |
References
- ↑ Martin S. Maron; Benjamin M. Kalsmith; James E. Udelson; Wenjun Li and David Denofrio.Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy.doi: 10.1161/CIRCHEARTFAILURE.109.922872